-
12:37:42 AM

DCTH Stock News

04/03/23 4:30 PM
Nasdaq : DCTH
low float
Delcath Systems Announces Resumption of Interest-Only Period for Company's Debt Facility
Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced it reached an agreement to amend its existing loan agreement with Avenue Venture Opportunities Fund, L.P.. The I/O period may be extended at Delcath's option to December 31, 2023 if, by September 30, 2023, Delcath has...
RHEA-AI
very positive
03/27/23 8:20 AM
Nasdaq : DCTH
low float
Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022. During and since the fourth quarter, Delcath Systems, Inc.:. Received an acceptance of the NDA resubmission...
RHEA-AI
neutral
03/27/23 8:10 AM
Nasdaq : DCTH
low float
Delcath Systems, Inc. Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023
Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the US Food and Drug Administration has accepted Delcath Systems, Inc.' s new drug application resubmission for HEPZATO™ Kit seeking approval for the treatment of patients with unresectable hepatic-dominant...
RHEA-AI
neutral
02/16/23 8:30 AM
Nasdaq : DCTH
managementlow float
Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch
Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that its Board of Directors has voted to appoint John R. Sylvester as Delcath's new Chairman. Mr. Sylvester has served as a Director of Delcath since July 2019 and has extensive experience building interventional...
RHEA-AI
very positive